📇 Rhumatologue · PARIS CEDEX 14 · (75) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
19 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP CUP SITE COCHIN PORT ROYAL
27 R DU FAUBOURG SAINT JACQUES, 75679 PARIS CEDEX 14
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
BMJ (Clinical research ed.) · 2020
Abstract Objective To assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen. Design Comparative observational study using data collected from routine care. Setting Four French tertiary care centres providing care to patients with covid-19 pneumonia between 12 March and 31 March 2020. Participants 181 patients aged 18-80 years with documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia who required oxygen but not intensive care. Interventions Hydroxychloroquine at a dose of 600 mg/day within 48 hours of admission to hospital (treatment group) versus standard care without hydroxychloroquine (control group). Main outcome measures The primary outcome was survival without transfer to the intensive care unit at day 21. Secondary outcomes were overall survival, survival without acute respiratory distress syndrome, weaning from oxygen, and discharge from hospital to home or rehabilitation (all at day 21). Analyses were adjusted for confounding factors by inverse probability of treatment weighting. Results In the main analysis, 84 patients who received hydroxychloroquine within 48 hours of admission to hospital (treatment group) were compared with 89 patients who did not receive hydroxychloroquine (control group). Eight additional patients received hydroxychloroquine more than 48 hours after admission. In the weighted analyses, the survival rate without transfer to the intensive care unit at day 21 was 76% in the treatment group and 75% in the control group (weighted hazard ratio 0.9, 95% confidence interval 0.4 to 2.1). Overall survival at day 21 was 89% in the treatment group and 91% in the control group (1.2, 0.4 to 3.3). Survival without acute respiratory distress syndrome at day 21 was 69% in the treatment group compared with 74% in the control group (1.3, 0.7 to 2.6). At day 21, 82% of patients in the treatment group had been weaned from oxygen compared with 76% in the control group (weighted risk ratio 1.1, 95% confidence interval 0.9 to 1.3). Eight patients in the treatment group (10%) experienced electrocardiographic modifications that required discontinuation of treatment. Conclusions Hydroxychloroquine has received worldwide attention as a potential treatment for covid-19 because of positive results from small studies. However, the results of this study do not support its use in patients admitted to hospital with covid-19 who require oxygen.
European journal of cancer (Oxford, England : 1990) · 2017
European heart journal · 2021
AbstractAimsThe aim of this study is to compare the Hestia rule vs. the simplified Pulmonary Embolism Severity Index (sPESI) for triaging patients with acute pulmonary embolism (PE) for home treatment.Methods and resultsNormotensive patients with PE of 26 hospitals from France, Belgium, the Netherlands, and Switzerland were randomized to either triaging with Hestia or sPESI. They were designated for home treatment if the triaging tool was negative and if the physician-in-charge, taking into account the patient’s opinion, did not consider that hospitalization was required. The main outcomes were the 30-day composite of recurrent venous thrombo-embolism, major bleeding or all-cause death (non-inferiority analysis with 2.5% absolute risk difference as margin), and the rate of patients discharged home within 24 h after randomization (NCT02811237). From January 2017 through July 2019, 1975 patients were included. In the per-protocol population, the primary outcome occurred in 3.82% (34/891) in the Hestia arm and 3.57% (32/896) in the sPESI arm (P = 0.004 for non-inferiority). In the intention-to-treat population, 38.4% of the Hestia patients (378/984) were treated at home vs. 36.6% (361/986) of the sPESI patients (P = 0.41 for superiority), with a 30-day composite outcome rate of 1.33% (5/375) and 1.11% (4/359), respectively. No recurrent or fatal PE occurred in either home treatment arm.ConclusionsFor triaging PE patients, the strategy based on the Hestia rule and the strategy based on sPESI had similar safety and effectiveness. With either tool complemented by the overruling of the physician-in-charge, more than a third of patients were treated at home with a low incidence of complications.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Thrombosis research · 2024 · Randomized Controlled Trial
Chaibi S, Roy PM, Guénégou AA, Tran Y, et al.
International journal of surgical pathology · 2024 · Case Reports
Baber A, Legendre P, Palmic P, Lupo-Mansuet A, et al.
Rheumatology (Oxford, England) · 2023 · Case Reports
Roeser A, Hadjadj J, Prat L, Szwebel TA, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Rasmussen C, Abitbol V, El Karoui K, Bourrier A, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2021 · Journal Article
Gendron N, Dragon-Durey MA, Chocron R, Darnige L, et al.
Angiogenesis · 2021 · Journal Article
Philippe A, Chocron R, Gendron N, Bory O, et al.
Journal of thrombosis and haemostasis : JTH · 2021 · Journal Article
Smadja DM, Philippe A, Bory O, Gendron N, et al.
Journal of clinical immunology · 2021 · Letter
Bastard P, Lévy R, Henriquez S, Bodemer C, et al.
Stem cell reviews and reports · 2021 · Case Reports
Szwebel TA, Veyer D, Robillard N, Eshagh D, et al.
Annals of the rheumatic diseases · 2018 · Letter
Le Burel S, Champiat S, Routier E, Aspeslagh S, et al.
Presse medicale (Paris, France : 1983) · 2013 · Evaluation Study
Goupy F, Abgrall-Barbry G, Aslangul E, Chahwakilian A, et al.
La Revue du praticien · 2011 · English Abstract
Szwebel TA, Le Jeunne C
European journal of cancer (Oxford, England : 1990) · 2017 · Journal Article
Le Burel S, Champiat S, Mateus C, Marabelle A, et al.
Thrombosis research · 2012 · Clinical Trial
Nuñez MJ, Villalba JC, Cebrián E, Visoná A, et al.
Journal of clinical medicine · 2022 · Journal Article
Chenevier-Gobeaux C, Ducastel M, Meritet JF, Ballaa Y, et al.
BMC gastroenterology · 2020 · Case Reports
Contejean A, Larousserie F, Bouscary D, Dohan A, et al.
BMJ (Clinical research ed.) · 2020 · Journal Article
Mahévas M, Tran VT, Roumier M, Chabrol A, et al.
European heart journal · 2021 · Journal Article
Roy PM, Penaloza A, Hugli O, Klok FA, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2026 · Journal Article
Chen P, Briançon H, Eshagh D, Szwebel TA, et al.
BMC gastroenterology · 2020 · Case Reports
Contejean A, Larousserie F, Bouscary D, Dohan A, et al.
Platelet activation in critically ill COVID-19 patients
Abstract Background Microvascular, arterial and venous thrombotic events have been largely described during severe coronavirus disease 19 (COVID-19). However, mechanisms underlying hemostasis dysregulation remain unclear
Platelet activation in critically ill COVID-19 patients
Abstract Background Microvascular, arterial and venous thrombotic events have been largely described during severe coronavirus disease 19 (COVID-19). However, mechanisms underlying hemostasis dysregulation remain unclear
Data from: Immune checkpoint inhibitor–related myositis and myocarditis in patients with cancer
Objective: To report the clinicopathological features and outcome of myositis in patients treated with immune checkpoint inhibitors (irMyositis). Methods: We retrospectively analyzed patients diagnosed with irMyositis
Supplementary Table 1. Detailed auto-antibodies work-up in patients with irMyositis.
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
✨ Profil synthétique
IA · 24/05/2026MME TALI-ANNE SZWEBEL est une rhumatologue hospitalière à Paris, impliquée dans des recherches sur le COVID-19, les myopathies inflammatoires et la thromboembolie veineuse. Elle a publié plus de 70 travaux et possède un h-index de 24. Ses recherches couvrent également l'épidémiologie, les biomarqueurs et les essais cliniques.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.